{"id":"tafluprost-and-dorzolamide-timolol","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation/discomfort"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Increased iris pigmentation"},{"rate":null,"effect":"Eyelash growth"}]},"_chembl":{"chemblId":"CHEMBL1963683","moleculeType":"Small molecule","molecularWeight":"452.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tafluprost is a prostaglandin F analogue that binds to the prostaglandin F receptor and increases uveoscleral (unconventional) outflow of aqueous humor. Dorzolamide is a topical carbonic anhydrase inhibitor that decreases aqueous humor production by inhibiting carbonic anhydrase in the ciliary body. Timolol is a non-selective beta-adrenergic antagonist that further reduces aqueous humor secretion. Together, these three agents provide complementary mechanisms to lower intraocular pressure.","oneSentence":"This combination reduces intraocular pressure by increasing uveoscleral outflow via prostaglandin F analogue activity and decreasing aqueous humor production via carbonic anhydrase inhibition and beta-blockade.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:01.727Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT04673604","phase":"NA","title":"From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-05-06","conditions":"Glaucoma, Ocular Surface Disease","enrollment":42},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Saflutan, Taflotan, Cosopt PF"],"phase":"marketed","status":"active","brandName":"tafluprost and dorzolamide/timolol","genericName":"tafluprost and dorzolamide/timolol","companyName":"Aristotle University Of Thessaloniki","companyId":"aristotle-university-of-thessaloniki","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces intraocular pressure by increasing uveoscleral outflow via prostaglandin F analogue activity and decreasing aqueous humor production via carbonic anhydrase inhibition and beta-blockade. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}